Printer Friendly


 SEATTLE, Sept. 17 /PRNewswire/ -- Immunex Corp. (NASDAQ: IMNX) today announced that the company's board of directors has appointed Steven Gillis, Ph.D. acting chairman and chief executive officer of the biopharmaceutical company, positions previously held by Stephen A. Duzan, until a permanent successor is named.
 Gillis, 40, is a co-founder of Immunex and has been executive vice president, director of research and development, and a member of the board since the company's inception in 1981. He currently serves as president and chief executive officer of Immunex Research and Development Corp., the company's research subsidiary. Gillis holds a doctorate in biological sciences from Dartmouth College.
 As previously announced, Duzan, who co-founded Immunex and for twelve years served as the company's chairman and chief executive, had elected to step down following a transition period once the firm's merger with American Cyanamid Co.'s (NYSE: ACY) North American oncology business was completed. The merger was effective on June 1, 1993.
 "The past several months have demonstrated the value of our existing management team. In addition to completing the merger of our two operations, they have continued to make progress in advancing our product pipeline," said Duzan. "As a co-founder of Immunex who has shared in defining our vision and has been responsible for developing our pipeline, Steve Gillis is the right person for this transitional period."
 "Our objective in the months ahead is unchanged," stated Gillis, "to maximize the potential of the second largest oncology product line in North America."
 An active search for a permanent chief executive continues, headed by Gillis and other Immunex board members Frank V. AtLee, III, president of American Cyanamid, and Michael L. Kranda, president of Immunex.
 Kranda continues as Immunex president and chief operating officer, with added responsibilities for legal affairs, finance and communications. David L. Urdal, Ph.D., president of Immunex's manufacturing subsidiary, has been appointed to temporarily fill the board seat vacated by Duzan. Once a new chief executive officer is selected, Gillis will continue in his current capacity as president of Immunex Research and Development Corp.
 Immunex Corp. is a biopharmaceutical company focused on the discovery, development, manufacture and marketing of innovative products to treat cancer and autoimmune diseases.
 -0- 9/17/93
 /NOTES TO EDITORS: Duzan co-founded Immunex in 1981 with Drs. Steven Gillis and Christopher Henney. He served as chairman of the Industrial Biotechnology Association from 1991 to 1993 and led that organization to merge with the Association of Biotechnology Companies to form a unified American biotechnology presence (the current Biotechnology Industry Organization). In Washington state, Duzan has served as governor-appointed chairman on several committees, including the Washington State Biotechnology Targeted Sector Advisory Committee, a position he held from 1989 through 1991.
 Gillis is an ad-hoc consultant to the National Cancer Institute's division of cancer treatment, a member of the Keystone Symposia Advisory Board, an editor or associate editor of several scientific journals and an adjunct professor in the University of Washington's department of immunology. He is also an author of more than 200 articles in the field of cytokine research./
 /CONTACT: Valoree Dowell or Mary McConnon of Immunex, 206-587-0430/

CO: Immunex Corp. ST: Washington IN: MTC SU: PER

JH -- SE002 -- 2948 09/17/93 08:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 17, 1993

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters